Gray Matter Changes in Parkinson's and Alzheimer's Disease and Relation to Cognition

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F19%3A00071706" target="_blank" >RIV/00159816:_____/19:00071706 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14740/19:00108545

Výsledek na webu

<a href="https://link.springer.com/article/10.1007%2Fs11910-019-1006-z" target="_blank" >https://link.springer.com/article/10.1007%2Fs11910-019-1006-z</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11910-019-1006-z" target="_blank" >10.1007/s11910-019-1006-z</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Gray Matter Changes in Parkinson's and Alzheimer's Disease and Relation to Cognition

Popis výsledku v původním jazyce

Purpose of Review We summarize structural (s)MRI findings of gray matter (GM) atrophy related to cognitive impairment in Alzheimer&apos;s disease (AD) and Parkinson&apos;s disease (PD) in light of new analytical approaches and recent longitudinal studies results. Recent Findings The hippocampus-to-cortex ratio seems to be the best sMRI biomarker to discriminate between various AD subtypes, following the spatial distribution of tau pathology, and predict rate of cognitive decline. PD is clinically far more variable than AD, with heterogeneous underlying brain pathology. Novel multivariate approaches have been used to describe patterns of early subcortical and cortical changes that relate to more malignant courses of PD. New emerging analytical approaches that combine structural MRI data with clinical and other biomarker outcomes hold promise for detecting specific GM changes in the early stages of PD and preclinical AD that may predict mild cognitive impairment and dementia conversion.

Název v anglickém jazyce

Gray Matter Changes in Parkinson's and Alzheimer's Disease and Relation to Cognition

Popis výsledku anglicky

Purpose of Review We summarize structural (s)MRI findings of gray matter (GM) atrophy related to cognitive impairment in Alzheimer&apos;s disease (AD) and Parkinson&apos;s disease (PD) in light of new analytical approaches and recent longitudinal studies results. Recent Findings The hippocampus-to-cortex ratio seems to be the best sMRI biomarker to discriminate between various AD subtypes, following the spatial distribution of tau pathology, and predict rate of cognitive decline. PD is clinically far more variable than AD, with heterogeneous underlying brain pathology. Novel multivariate approaches have been used to describe patterns of early subcortical and cortical changes that relate to more malignant courses of PD. New emerging analytical approaches that combine structural MRI data with clinical and other biomarker outcomes hold promise for detecting specific GM changes in the early stages of PD and preclinical AD that may predict mild cognitive impairment and dementia conversion.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Neurology and Neuroscience Reports

ISSN

1528-4042

e-ISSN

—

Svazek periodika

19

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

—

Kód UT WoS článku

000497702100001

EID výsledku v databázi Scopus

—